Multiple needle injector

Information

  • Patent Grant
  • 10433928
  • Patent Number
    10,433,928
  • Date Filed
    Thursday, March 10, 2016
    9 years ago
  • Date Issued
    Tuesday, October 8, 2019
    5 years ago
Abstract
An improved injector needle apparatus is described with inherent properties for increasing linear flow rates when inserted into a subcutaneous port during tissue expansion thus decreasing procedure time.
Description
FIELD OF THE INVENTION

The present invention is generally directed to an apparatus using a plurality of needles to increase flow rates during tissue expansion and injection of fluids into subcutaneous tissue and the method thereof.


BACKGROUND OF THE INVENTION

Breast reconstruction is one of the most common procedures performed in plastic surgery today. One out of eight women will have breast cancer in their lifetime, the majority of whom will undergo reconstruction. Currently federal law mandates that any woman who has breast cancer must be offered reconstruction. Last year 96,000 breast reconstructions were performed, the vast majority of which were expander implant based reconstructions. Of note, many cases are bilateral, and therefore over 100,000 expanders are being utilized in breast reconstruction ever year.


The typical breast reconstruction process involves placing a deflated tissue expander in the chest pocket after mastectomy (breast removal). The expander includes a port through which sterile saline can be forced, causing the volume of the expander to increase. The expander is usually filled with sterile saline in the operating room prior to closing the surgical opening in the skin. The patient then returns to the clinic two weeks later for further expansion. Because the port is covered by skin, the port is located with the aid of a port locator magnet. Once it is located, a needle is placed through the skin into the port and sterile saline is injected. This procedure is done on a weekly basis until the skin envelope is expanded to a large enough size to accommodate the desired implant size for an appropriately sized breast mound. Typically, the expansion procedure is performed four to eight separate times prior to being ready for the expander/implant exchange.


This procedure is not limited to breast reconstruction. Tissue expanders are also used in burn reconstruction and various other types of reconstruction where skin expansion is needed.


The most pressing issue associated with breast and other types of tissue expansion is the exceedingly narrow needle used in current systems, such as the MENTOR brand winged infusion set, as compared to the pipe diameter of the rest of the system. The entire system is bottlenecked by the 21 gauge needle that is used to inject the port. The inner diameter of the needle is 0.51 mm (outer diameter 0.81 mm), which is the maximum allowable gauge needle per the manufacturer instructions (see Mentors Product Website) due to the nature of the port. Narrow needles result in slow flow of sterile saline, and require more time to fill the tissue expander. The filling process in the operating room can be as long as 10 to 15 minutes during which time the surgeons and nurse must patiently wait for the expander to fill with the patient still open. Simply a larger needle would core out the silicone and make the port leak, and thus fail.


SUMMARY OF THE INVENTION

We disclose herein a fluid injector apparatus for injecting fluid through a plurality of needles into a subcutaneous port during tissue expansion comprising a base, tubing connecting the needles, and a base fluid injection system to increase linear flow velocity and decrease procedure time.


We also disclose a method of injecting fluid through a plurality of needles into a subcutaneous port during tissue expansion comprising a base, tubing connecting the needles, and a base fluid injection system to increase linear flow velocity and decrease procedure time.





BRIEF DESCRIPTION OF THE DRAWINGS

Further advantages of the invention will become apparent by reference to the detailed description of preferred embodiments when considered in conjunction with the drawings:



FIG. 1 is a top plan view of the multiple injector needle apparatus.



FIG. 2 is a front view of the multiple injector needle apparatus.



FIG. 3 is a front view of a plastic sleeve for needle protection.



FIG. 4 is a perspective view of the multiple injector needle apparatus.



FIG. 5 is a top plan view of the multiple injector needle apparatus.



FIG. 6A-6D are views of an embodiment of the multiple injector needle apparatus. Independently, FIG. 6A is a perspective view of the hub of the apparatus. FIG. 6B is a cross-sectional view of the multiple injector needle apparatus. FIG. 6C is a top plan view of the hub of the apparatus. FIG. 6D is a cross sectional view of the hub of the apparatus taken along the line 6D-6D of FIG. 6B.



FIG. 7A-7D are views of an embodiment of the multiple injector needle apparatus. Independently, FIG. 7A is a perspective view of the hub of the apparatus. FIG. 7B is a top plan view of the hub of the apparatus. FIG. 7C is a cross-sectional view of the aggregating cone of the apparatus taken along the line 7C-7C of FIG. 7B, FIG. 7D is a cross-sectional view of the aggregating cone of FIG. 7C of the apparatus at increased magnification.



FIG. 8A-8C are views of an embodiment of the apparatus with needles inserted into the hub. Independently, FIG. 8A is a perspective view of the hub of the apparatus. FIG. 8B is a right side view of the hub of the apparatus. FIG. 8C is a cross-sectional view of the needles and hub of the apparatus.



FIG. 9A-9C are views of an embodiment of the apparatus with needles inserted into the hub. Independently, FIG. 9A is a perspective view of the hub of the apparatus. FIG. 9B is a right side view of the hub of the apparatus. FIG. 9C is a cross-sectional view of the aggregating cone of the apparatus.



FIG. 10 is a cross sectional view of an embodiment of the hub of the apparatus.



FIG. 11 is a cross sectional view of an embodiment of the hub of the apparatus with needles inserted.





DETAILED DESCRIPTION

The following detailed description is presented to enable any person skilled in the art to make and use the invention. For purposes of explanation, specific details are set forth to provide a thorough understanding of the present invention. However, it will be apparent to one skilled in the art that these specific details are not required to practice the invention. Descriptions of specific applications are provided only as representative examples. Various modifications to the preferred embodiments will be readily apparent to one skilled in the art, and the general principles defined herein may be applied to other embodiments and applications without departing from the scope of the invention. The present invention is not intended to be limited to the embodiments shown, but is to be accorded the widest possible scope consistent with the principles and features disclosed herein.


To overcome the issue of the slow flow through a single injection needle, our invention uses a plurality of needles. The typical injection port is nearly 3 cm in diameter. So, while a large single needle would cause failure, multiple small needles can easily be placed into the silicone dome at the same time without breaking the seal. The present invention (as pictured in FIG. 2) would solve the exceedingly small needle issue by allowing for a four (4) times increase in the flow velocity as compared to the current standard and sole existing option by allowing a plurality of separate needles contained within one construct at the end of butterfly tubing thus resulting in immense time savings in the operating room as well as the clinic.


We disclose herein such an apparatus that allows for increased flow rate of fluids into a tissue expander. The apparatus has multiple needles that can be simultaneously inserted into the port, thus allowing more fluid to flow into the expander. As a result of the increased flow, the time to fill the tissue expander is significantly reduced.


Referring to the drawings, FIG. 2 illustrates the multiple needle apparatus 1 consisting primarily of needles 2 projecting outward from a hub 5 and tubing 4 for connecting the hub to a fluid source.


The needles 2 project from the first end (injection side) of the hub 5 such that they are substantially parallel to each other. As shown in FIG. 1 and FIG. 4, the needles are spaced such that all of them can simultaneously enter the injection port on the breast tissue expander. In the example shown, the needles are spaced no more than five (5) millimeters across. The needles 2 may be shorter than currently used needles, or they may have ultra-thin walls, thus reducing the pressure required for increased flow of fluid into the tissue expander. Any type and sized of needle that allows the flow of liquid may be used in the device, although in a preferred embodiment, a standard hypodermic will be used in the apparatus 1.


It should be appreciated that any size hub 5 may be selected to accommodate a plurality of needles. In the embodiments depicted in FIG. 6, the hub 5 may be as large as three (3) centimeters in diameter or as small as one-quarter (0.25) of a centimeter in diameter. Also, the needles may be secured into the hub by pressure as shown in FIG. 8A-8C or secured into the hub by glue as shown in FIG. 9A-9C.


Opposite the needle side of the hub 5 lies the second end 6 of the hub. The second end 6 is configured to receive IV tubing. In the example shown, butterfly IV tubing would connect to the second end 6. As shown in FIG. 6A, the hub 5 ideally would be made of plastic, and would have plastic handles 7 that would aid in the insertion of the needles into the injection port.


As shown in FIG. 4, the preferred embodiment of the apparatus has four 4.5 cm long 21 gauge needles 2 situated parallel precise placement into the silicone dome of the subcutaneous port during a tissue expansion procedure, thus increasing linear flow rate into the apparatus 1. In this embodiment, the actual diameter of the preferred embodiment of the hub 5 is approximately 5 millimeters. Tubing 4 attaches to hub 5 at second end 6 by stretching the tubing over the second end 6 of the hub. It should be appreciated that although the hub is shown as having a permanent connection to the tubing, it can be constructed such that the tubing is detachable. Tubing 4 terminates at the other end in a female connection of the leur lock base 3.


As shown in FIG. 10, a potential embodiment of the tubing 4 connection to the huh 5 includes the entry portal for the tubing 4 having an inner diameter equal to the outer diameter of the tubing 4. The tubing 4 is securely attached to the second end 6 of the hub 5 allowing unimpeded fluid flow through the tubing 4 into the hub 5, as shown in FIG. 11.


To use the apparatus 1, leur lock base 3 is attached to a fluid source, such as a syringe. The fluid is then pushed through the tubing 4.


As shown in FIG. 6A-6D, the preferred embodiment of the apparatus 1 has a graded directing wall 8 with the narrowest portion at the fluid entry point (diameter of the tubing 4) and the widest portion at the fluid exit point (the plurality of needles 2) as pictured in FIG. 6B. As shown FIG. 6C, the gradual change in diameter of the system created by this angled directing wall 8 improves laminar flow.


As the fluid passes through the hub 5, it is distributed into the plurality of needles 2 via a directing cone 9. The directing cone 9 encourages and directs flow from the proximal end of the hub 5 into the needles 2. Without the directing cone 9, the fluid would require a 90 degree change in direction to enter the plurality of needles 2. Therefore, the increased directional flow in a graduated manner created by the directing cone 9 improves laminar flow, thus improving the actualized flow rate of the apparatus 1.


When the needles are filled with fluid, the needles are inserted into the injection port of the tissue expander, and the fluid the fills the tissue expander.


Potential embodiments of the needles 2 including a plurality of hypodermic needles, conical needles, taper needles or 1.5 inch needles where the diameter actually tapers from a larger gauge (i.e. 18 gauge) to a smaller 21 gauge size by point in the needle where the port puncture occurs, as the 21 gauge segment is required only for the portion that enters the port. Additionally, thin walled needles approaching six (6) times thinner that the standard needle wall are contemplated as an embodiment of the instant invention.


Another potential embodiment of the needles 2 includes ultra-thin wall 21 gauge needles that maintain the same external diameter of 0.81 millimeter, but a larger internal diameter.


As shown in FIG. 2, the preferred embodiment of the invention has a leur lock base 3 to allow for secure attachment of a syringe or other fluid source.


As shown in FIG. 2, the preferred embodiment of the invention consists of approximately 11 inches of IV tubing 4 to connect the needles. It should be appreciated, however, that the apparatus 1 can include any type or length of tubing 5 capable of connecting the needles 2.


As shown in FIG. 6B and FIG. 7C-7D, a potential embodiment of the invention consist of a cone-shaped cut out in the hub 5 that directs fluid flow from the base 3 into the needle 2 in a graduated manner. As shown in FIG. 7D, this aggregating cone 10 has a diameter equal to one half of the internal diameter of the hub 5 minus the diameter of the directing cone 9 (Formulaically: DAC=½(Dhub−DDC). Thus, surrounding each needle base, there is a graded wall, consisting of an internal gradual decrease in the diameter of the base leading to the needle, to channel fluid flow from the widest portion of the directing wall 8 to the base of the directing cone 9 and increase laminar flow rates.


Other potential embodiments of the IV tubing 4 include no rolling ball lock to stop IV flow; wider tubing to allow improved flow especially in the butterfly segment; a series of one-way valves instead of the four way stopcock to create a “no-touch” system allowing drawing and injecting into the port without manually turning the stocking into the correct position; and an autoinjector that prefills the syringe with a preset amount of saline (i.e. 35, 50, or 60 cc). The one-way valves would require two one-way valves allowing for inflow from the IV bag and out flow through the needle side, and the autoinjeetor could be created with a plastic handle and preloaded spring that draws back on the syringe to the desired level.


In another potential embodiment, the invention can be used in subcutaneous ports requiring high volume filling with fluid or fluidic suspension, such as in breast tissue and subcutaneous tumescence.


It should be appreciated that the invention can also have a fluid injection system including a series of valves, tubing, syringe and NaCL 0.9% IV fluid reservoir.


As shown in FIG. 3, the apparatus 1 may include a plastic sleeve 11, to protect the needles 2 when not in use.


To demonstrate the efficiency of the instant invention compared to the current standard, we performed flow velocity measurements in a single-blind study as shown in Table 1. The measurements for the current standard were taken using a BRAUN brand 21 gauge winged needle infusion set 7B3050. The instant invention incorporated four 21 gauge hypodermic needles.









TABLE 1







Flow velocity data of the instant invention and the current standard reported as time to inject and the corresponding time savings of using the instant invention rather than the current standard.


Multiple Injector Needle vs. Braun 21 g Injector Data (in seconds)











Multiple Injector





Needle - Time to
Braun 21 g - Time



Simulation
Inject
to Inject
Time Savings













1
6.600
25.500
18.900


2
7.000
29.000
22.000


3
6.900
27.800
20.900


4
6.800
26.800
20.000


5
6.900
25.500
18.600


6
7.100
27.200
20.100


7
6.200
26.500
20.300


8
6.300
27.300
21.000


9
6.800
28.400
21.600


10
6.500
28.200
21.700


11
5.300
22.600
17.300


12
5.400
24.300
18.900


13
5.700
23.900
18.200


14
5.300
23.100
17.800


15
5.400
24.400
19.000


16
5.200
23.900
18.700


17
5.500
24.500
19.000


18
5.300
23.800
18.500


19
6.100
23.600
17.500


20
5.200
24.200
19.000


Ave.
6.075
25.525
19.450


Std. Dev.
0.709
1.963
1.419









As shown in Table 1, the evaluation conducted showed that the multiple injector needle average flow rate is 4.2-fold greater than the BRAUN 21 g winged needle infusion set 7B3050. The average time for injection for twenty (20) trials wherein the apparatuses were filled with 60 cc of fluid was 6.075 seconds for the multiple injector needle, while the BRAUN 21 g standard took 25.525 seconds. The standard deviation for each apparatus was 0.71 and 1.96 seconds, respectively. The two-tailed P value for this evaluation was less than 0.0001, which, considered by conventional criteria, is an extremely statistically significant difference. Also, the mean of the multiple injector needle minus the current standard equals 19.450 seconds with a 95% confidence interval for this difference from 18.507 to 20.393. It should be appreciated that the instant invention using four needles results in greater than fourfold increase in injection rate.


Based on the results of this evaluation, the greater than four times increased flow velocity of the instant invention results in the tedious and painful injection process being much more comfortable to perform. With less force required for injection, less body bruising from pressing against the ribs or abdomen, and less thumb injury will result. For instance, the basal joint of the thumb sees a thirteen (13) times increased load from that created at the site of compression. If you press the syringe with your thumb with twenty (20) pounds per square inch of pressure, your thumb basal joint sees two hundred and sixty (260) pounds per square inch, decreasing the risk of the development of arthritis due to conducting such an injection. Most importantly, faster injection corresponds to faster surgery time with the patient under anesthesia for less time. Accordingly, patients will have better recovery periods, lower chances for infection, and likely faster discharge from the hospital due to the time savings provided by the instant invention.


Further, the faster process associated with the multiple injector needle will likely save total procedure time resulting in cost savings. For instance, in a bilateral reconstruction procedure, the faster process will likely save upwards of ten (10) minutes with moderate intraoperative fill volumes. This cost savings is quantified via a 2005 peer-reviewed study with average cost of $62.00 per minute. This cost does not include anesthesia costs, nor the expense of consumables. Thus, actual savings are even higher.


Also, as shown in Table 2, we measured fluid released from the port during injection to determine leakage of the instant invention.









TABLE 2







Leakage data of the multiple injector needle after being inserted and removed into the center of a port thirty (30) times


Leakage Data Log










Day
Leak






1-3
No



4-6
No



7-9
No



10-12
No



13-15
No



16-18
No



19-21
No



22-24
No



25-27
No



28-30
No



31-33
No



34-37
No



38-40
No



41-43
No



44-47
No



48-50
No



51-53
No



54-57
No



58-60
No



61-63
No



64-66
No



67-69
No



70-72
No



73-75
No



76-78
No



79-81
No



82-84
No



85-87
No



88-90
No



91-93
N/A









As shown in Table 2, no tissue expanders were found to be leaking following ninety (90) days of inspection. The multiple injector needle was used in three (3) different tissue expander samples (1 Mentor; 2 Allergan), and fluid was injected into the apparatus as well. The apparatus was turned upside down so that the port was at the lowest point and then wiped dry. Compression of the multiple injector needle with manual pressure was performed with the port at the lowest point in relationship to gravity. Visible and palpable testing was performed to look for any evidence of fluid released from the port. The lack of data leakage associated with the instant invention further indicates the reliability and efficiency of the design of the instant invention.


Although the invention has been described herein as being used with breast tissue expanders, it is contemplated that it can be used in any tissue expander or in any other device with an injection port that can accommodate multiple needles.


The terms “comprising,” “including,” and “having,” as used in the claims and specification herein, shall be considered as indicating an open group that may include other elements not specified. The terms “a,” “an,” and the singular forms of words shall be taken to include the plural form of the same words, such that the terms mean that one or more of something is provided. The term “one” or “single” may be used to indicate that one and only one of something is intended. Similarly, other specific integer values, such as “two,” may be used when a specific number of things is intended. The terms “preferably,” “preferred,” “prefer,” “optionally,” “may,” and similar terms are used to indicate that an item, condition or step being referred to is an optional (not required) feature of the invention.


The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention. It will be apparent to one of ordinary skill in the art that methods, devices, device elements, materials, procedures and techniques other than those specifically described herein can be applied to the practice of the invention as broadly disclosed herein without resort to undue experimentation. All art-known functional equivalents of methods, devices, device elements, materials, procedures and techniques described herein are intended to be encompassed by this invention. Whenever a range is disclosed, all subranges and individual values are intended to be encompassed. This invention is not to be limited by the embodiments disclosed, including any shown in the drawings or exemplified in the specification, which are given by way of example and not of limitation.


While the invention has been described with respect to a limited number of embodiments, those skilled in the art, having benefit of this disclosure, will appreciate that other embodiments can be devised which do not depart from the scope of the invention as disclosed herein. Accordingly, the scope of the invention should be limited only by the attached claims.


All references throughout this application, for example patent documents including issued or granted patents or equivalents, patent application publications, and non-patent literature documents or other source material, are hereby incorporated by reference herein in their entireties, as though individually incorporated by reference, to the extent each reference is at least partially not inconsistent with the disclosure in the present application (for example, a reference that is partially inconsistent is incorporated by reference except for the partially inconsistent portion of the reference).

Claims
  • 1. A fluid injection device comprising: a plurality of needles;a hub having a first end portion, a second end portion, a plurality of needle bases at the second end portion, and a directing cone extending from the second end portion with the plurality of needle bases at least partially surrounding the directing cone, the directing cone tapering to a non-frustoconical tip in a direction away from the first end portion for diverting flow toward the plurality of needle bases, each of said plurality of needles being in fluid communication with a respective one of the plurality of needle bases and projecting from said first end portion of the hub; anda base component, separate from and couplable to a second end portion of the hub, the non-frustoconical tip extending into a cavity of the base component, upstream of the plurality of needle bases, the base component comprising an inlet configured to receive tubing therein for connecting the device to a fluid source.
  • 2. The device of claim 1, wherein said plurality of needles consists of at least two needles.
  • 3. The device of claim 1, wherein said plurality of needles consists of four needles.
  • 4. The device of claim 1, wherein said needles consist of hypodermic needles.
  • 5. The device of claim 1, wherein said needles consist of 21 gauge needles.
  • 6. The device of claim 1, wherein said needles are conical.
  • 7. The device of claim 1, further comprising a base member coupled to the second end portion, wherein the base member is configured to be coupled to tubing having a terminal portion having a female luer lock base.
  • 8. The device of claim 1, wherein said hub is made of plastic.
  • 9. The device of claim 1, wherein said hub includes handles for enabling easier insertion of the needles into an injection port.
  • 10. The device of claim 1, wherein said hub has graded walls surrounding the needle bases to increase laminar flow.
  • 11. The device of claim 1, wherein said needles are ultra-thin wall needles, wherein the ultra-thin wall needles maintain the same external diameter as standard needles of the same size, but have a larger internal diameter than standard needles of the same size.
  • 12. The device of claim 1, wherein said needles are configured to simultaneously enter an injection port of a tissue expander.
  • 13. A fluid injection device comprising a hub and a base component, the hub having a first end portion, a second end portion, and a plurality of needle bases formed along said second end portion, said first end portion is configured to receive a plurality of needles to permit the plurality of needles to project from said first end portion of the hub, each of the plurality of needles being in fluid communication with a respective needle base, the hub further comprising a directing surface (i) being angled toward the needle bases and (ii) having a tapered shape that terminates in a non-frustoconical tip, the needle bases being arranged around the directing surface to promote laminar flow of a fluid along the directing surface toward the needle bases, the base component, separate from and couplable to a second end portion of the hub, the non-frustoconical tip extending into a cavity of the base component, upstream of the plurality of needle bases, the base component comprising an inlet configured to receive tubing therein for connecting the device to a fluid source.
  • 14. A method of increasing fluid flow into an injection port of a tissue expander comprising the steps of: a. providing a hub and a base component coupled to a tubing attached to a fluid source, wherein said hub has a first end portion from which a plurality of needles project outward and a second end portion configured to receive fluid from the tubing, each of the plurality of needles being in fluid communication with a needle base formed along said second end portion, the hub further comprising a directing surface (i) being angled toward and at least partially surrounded by the needle bases and (ii) having a tapered shape that terminates in a non-frustoconical tip to promote laminar flow of a fluid toward the needle bases, the base component being separate from and couplable to a second end portion of the hub, the non-frustoconical tip extending into a cavity of the base component, upstream of the plurality of needle bases, the base component comprising an inlet configured to receive the tubing therein for connecting the hub to the fluid source; andb. pushing fluid through said tubing such that said fluid passes through the hub and into each of the plurality of needles.
  • 15. The method of claim 14, further comprising: inserting said needles into a subcutaneous port.
  • 16. The device of claim 13, wherein the directing surface comprises a directing cone.
  • 17. The device of claim 13, wherein the directing surface comprises a directing wall.
  • 18. The device of claim 13, wherein the plurality of needles are hypodermic needles.
  • 19. The device of claim 1, wherein the plurality of needles are spaced no more than about 5 millimeters apart.
  • 20. The device of claim 1, wherein the hub has a diameter in the range of about 0.25 cm to about 3 cm in diameter.
  • 21. A multiple injector apparatus comprising a hub, a plurality of needle bases in the hub, a plurality of needles coupled to the hub and in fluid communication with the plurality of needle bases, a solid-core directing cone extending from the hub and tapering in direction away from the plurality of needle bases to a non-frustoconical tip for diverting flow toward the plurality of needle bases, and a base component, separate from and couplable to a second end portion of the hub, the non-frustoconical tip extending into a cavity of the base component, upstream of the plurality of needle bases, the base component comprising an inlet configured to receive tubing therein for connecting the apparatus to a fluid source.
  • 22. The apparatus of claim 21, wherein the non-frustoconical tip is rounded.
  • 23. The apparatus of claim 21, wherein the base component comprises a tubing connection section and a central section interposed between the tubing connection section and the cavity, at the tubing connection section having a first diameter, the central section comprising a second diameter, smaller than the first diameter.
  • 24. The device of claim 1, wherein the non-frustoconical tip is rounded.
  • 25. The device of claim 1, wherein the base component comprises a tubing connection section and a central section interposed between the tubing connection section and the cavity, at the tubing connection section having a first diameter, the central section comprising a second diameter, smaller than the first diameter.
  • 26. The device of claim 13, wherein the non-frustoconical tip is rounded.
  • 27. The device of claim 13, wherein the base component comprises a tubing connection section and a central section interposed between the tubing connection section and the cavity, at the tubing connection section having a first diameter, the central section comprising a second diameter, smaller than the first diameter.
  • 28. The method of claim 14, wherein the non-frustoconical tip is rounded.
  • 29. The method of claim 14, wherein the base component comprises a tubing connection section and a central section interposed between the tubing connection section and the cavity, at the tubing connection section having a first diameter, the central section comprising a second diameter, smaller than the first diameter.
CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/131,064, filed Mar. 10, 2015, which is incorporated herein by reference in its entirety.

US Referenced Citations (446)
Number Name Date Kind
1250114 Bigelow et al. Dec 1917 A
1558037 Morton Oct 1925 A
1591021 Davis Jul 1926 A
2007140 Ragnar Jul 1935 A
2302986 Vollrath Nov 1942 A
2491978 Helfman Dec 1949 A
2551902 Rieck May 1951 A
2737946 Hein, Jr. Mar 1956 A
2853070 Julliard Sep 1958 A
3086530 Groom Apr 1963 A
3161323 Bent Dec 1964 A
D202754 Fnftolin Nov 1965 S
D214112 Langdon May 1969 S
3517668 Brickson Jun 1970 A
3595231 Pistor Jul 1971 A
D224066 McDonald Jun 1972 S
3720211 Kyrias Mar 1973 A
3767085 Cannon et al. Oct 1973 A
3807048 Malmin Apr 1974 A
3910282 Messer et al. Oct 1975 A
3916777 Earl Nov 1975 A
4064879 Leibinsohn Dec 1977 A
4240423 Akhavi Dec 1980 A
4240426 Akhavi Dec 1980 A
4273122 Whitney et al. Jun 1981 A
4326517 Whitney et al. Apr 1982 A
4346708 Leeven Aug 1982 A
4444560 Jacklich Apr 1984 A
4529401 Leslie et al. Jul 1985 A
4605691 Balazs et al. Aug 1986 A
4617016 Blomberg Oct 1986 A
4624659 Goldberg Nov 1986 A
4627444 Brooker Dec 1986 A
4671255 Dubrul et al. Jun 1987 A
4695273 Brown Sep 1987 A
4699612 Hamacher Oct 1987 A
4710172 Jacklich Dec 1987 A
4719918 Bonomo et al. Jan 1988 A
4755169 Samoff Jul 1988 A
4759750 Devries Jul 1988 A
4800901 Rosenberg Jan 1989 A
4832692 Box May 1989 A
4841948 Bauer et al. Jun 1989 A
4841992 Sasaki et al. Jun 1989 A
4846886 Fey et al. Jul 1989 A
D303010 Jabbusch Aug 1989 S
4869717 Adair Sep 1989 A
4898572 Surugue nee Lasnier Feb 1990 A
4908029 Bark et al. Mar 1990 A
4909932 Monnet Mar 1990 A
4955905 Reed Sep 1990 A
4957744 dellaValle et al. Sep 1990 A
5024613 Vasconcellos Jun 1991 A
5024656 Gasaway et al. Jun 1991 A
5046506 Singer Sep 1991 A
5066303 Bark et al. Nov 1991 A
5092348 Dubrul et al. Mar 1992 A
5100390 Lubeck et al. Mar 1992 A
5104375 Lubeck et al. Mar 1992 A
5116358 Granger et al. May 1992 A
5127436 Campion et al. Jul 1992 A
5137181 Keller Aug 1992 A
5141496 Dalto et al. Aug 1992 A
5211644 VanBeek et al. May 1993 A
5258013 Granger et al. Nov 1993 A
5270685 Hagen Dec 1993 A
5279544 Gross Jan 1994 A
5295980 Ersek Mar 1994 A
5305788 Mayeux Apr 1994 A
5318544 Drypen Jun 1994 A
5322511 Armbruster et al. Jun 1994 A
5344407 Ryan Sep 1994 A
5354279 Hofling Oct 1994 A
5368572 Shirota Nov 1994 A
5383851 Mackinnon, Jr. Jan 1995 A
5405330 Zunitch et al. Apr 1995 A
5433352 Ronvig Jul 1995 A
5478327 McGregor et al. Dec 1995 A
5520658 Holm May 1996 A
5540657 Kurjan Jul 1996 A
5549672 Maddock et al. Aug 1996 A
5584815 Pawelka et al. Dec 1996 A
5611809 Marshall et al. Mar 1997 A
D378939 Smith et al. Apr 1997 S
5650317 Chang et al. Jul 1997 A
5690618 Smith et al. Nov 1997 A
5716404 Vacanti Feb 1998 A
5722829 Wilcox et al. Mar 1998 A
5728077 Williams Mar 1998 A
5752970 Yoon May 1998 A
5807340 Pokras Sep 1998 A
5814511 Chang et al. Sep 1998 A
5817033 DeSantis Oct 1998 A
5824335 Dorigatti et al. Oct 1998 A
5846225 Rosengart et al. Dec 1998 A
5853388 Semel Dec 1998 A
5941845 Tu et al. Aug 1999 A
5964737 Caizza Oct 1999 A
5972385 Liu et al. Oct 1999 A
6047861 Vidal et al. Apr 2000 A
D424194 Holdaway et al. May 2000 S
6077251 Ting et al. Jun 2000 A
6082364 Balian et al. Jul 2000 A
6083912 Khouri Jul 2000 A
6102929 Conway et al. Aug 2000 A
6129761 Hubbell et al. Oct 2000 A
6159233 Matsuzawa Dec 2000 A
6171276 Lippe Jan 2001 B1
6171610 Vacanti et al. Jan 2001 B1
6176396 Hamada et al. Jan 2001 B1
6183434 Eppstein Feb 2001 B1
D441077 Garito et al. Apr 2001 S
6214045 Corbitt, Jr. et al. Apr 2001 B1
6231552 Jentzen May 2001 B1
6231570 Tu et al. May 2001 B1
6239105 Brewitt et al. May 2001 B1
6283951 Flaherty et al. Sep 2001 B1
6293925 Safabash et al. Sep 2001 B1
6303518 Aceti Oct 2001 B1
6312412 Saied Nov 2001 B1
6316247 Katz Nov 2001 B1
6432046 Yarush et al. Aug 2002 B1
6451240 Sherman et al. Sep 2002 B1
6482187 Gibbs Nov 2002 B1
6488651 Morris Dec 2002 B1
6551290 Elsberry et al. Apr 2003 B1
6582960 Martin et al. Jun 2003 B1
6595960 West et al. Jul 2003 B2
6607512 Oliver Aug 2003 B2
6607513 Down Aug 2003 B1
6610033 Melanson et al. Aug 2003 B1
6611707 Prausnitz et al. Aug 2003 B1
6613010 Castellano Sep 2003 B2
6616448 Friedman Sep 2003 B2
6638308 Corbitt Oct 2003 B2
D483116 Castellano Dec 2003 S
6656488 Yi et al. Dec 2003 B2
6666893 Burg et al. Dec 2003 B2
6689095 Garitano et al. Feb 2004 B1
6689103 Palasis Feb 2004 B1
6716190 Glines Apr 2004 B1
6777231 Katz et al. Aug 2004 B1
6780171 Gabel Aug 2004 B2
6783514 Tovey et al. Aug 2004 B2
6824526 Castellano Nov 2004 B2
6881226 Corbitt Apr 2005 B2
6896666 Kochamba May 2005 B2
6901850 Corominas Jun 2005 B2
6908453 Fleming Jun 2005 B2
6916603 Baron et al. Jul 2005 B2
6936297 Roby et al. Aug 2005 B2
6945952 Kwon Sep 2005 B2
6991652 Burg et al. Jan 2006 B2
7004928 Aceti Feb 2006 B2
7015037 Furcht et al. Mar 2006 B1
7018356 Wise et al. Mar 2006 B2
7033337 Hjertman Apr 2006 B2
7041088 Nawrocki et al. May 2006 B2
7047070 Wilkinson et al. May 2006 B2
7048729 Meglin et al. May 2006 B2
7097631 Trautman Aug 2006 B2
7108681 Gartstein Sep 2006 B2
7115108 Wilkinson et al. Oct 2006 B2
7129209 Rhee et al. Oct 2006 B2
7150726 Dalton Dec 2006 B2
7285266 Voumakis et al. Oct 2007 B2
7302885 Townsend Dec 2007 B2
7316822 Binette et al. Jan 2008 B2
7361163 Cohen Apr 2008 B2
7390484 Fraser Jun 2008 B2
7419472 Hibner et al. Sep 2008 B2
7442187 Khayal et al. Oct 2008 B2
7445793 Niwa et al. Nov 2008 B2
7494473 Eggers et al. Feb 2009 B2
7501115 Fraser et al. Mar 2009 B2
7504386 Pressato et al. Mar 2009 B2
7514075 Hedrick et al. Apr 2009 B2
7556615 Pettis et al. Jul 2009 B2
7559952 Pinchuck Jul 2009 B2
7560276 Harmon et al. Jul 2009 B2
7588547 Deem Sep 2009 B2
7611495 Gianturco Nov 2009 B1
7651475 Angel Jan 2010 B2
7651684 Hedrick et al. Jan 2010 B2
7662110 Flaherty Feb 2010 B2
7664545 Westersten et al. Feb 2010 B2
7666339 Chaouk et al. Feb 2010 B2
D615192 Mudd et al. May 2010 S
7722582 Lina et al. May 2010 B2
7762983 Arnissolle Jul 2010 B2
7767452 Kleinsek et al. Aug 2010 B2
7799767 Lamberti et al. Sep 2010 B2
7850656 McKay et al. Dec 2010 B2
7850683 Elkins Dec 2010 B2
7875296 Binette et al. Jan 2011 B2
7878981 Strother et al. Feb 2011 B2
7896837 Wilkinson et al. Mar 2011 B2
D637287 Mudd et al. May 2011 S
7998170 Cunningham Aug 2011 B2
8012139 McKay et al. Sep 2011 B2
8029460 Rush et al. Oct 2011 B2
8053423 Lamberti et al. Nov 2011 B2
8066629 Dlugos Nov 2011 B2
8066691 Khouri Nov 2011 B2
8083722 McKay Dec 2011 B2
8088108 Kraft Jan 2012 B2
8137705 Doyle et al. Mar 2012 B2
8153591 Masters et al. Apr 2012 B2
8157830 Wenchell Apr 2012 B2
8172815 Down et al. May 2012 B2
8216190 Gartstein Jul 2012 B2
8236021 Kluge Aug 2012 B2
8291768 Spiegel Oct 2012 B2
8303518 Aceti Nov 2012 B2
8303545 Schraga Nov 2012 B2
8343132 Heneveld et al. Jan 2013 B2
8349554 Bahrami et al. Jan 2013 B2
8353871 Zimmerman Jan 2013 B2
8366643 Deem Feb 2013 B2
8394118 Jones et al. Mar 2013 B2
8409147 Kraft Apr 2013 B2
8409185 Burger Apr 2013 B2
8480630 Mudd et al. Jul 2013 B2
8535278 Mudd et al. Sep 2013 B2
8562571 Mudd et al. Oct 2013 B2
8603028 Mudd et al. Dec 2013 B2
8632501 Kraft Jan 2014 B2
8636797 Chitre et al. Jan 2014 B2
8657786 Bahrami et al. Feb 2014 B2
8668675 Chase Mar 2014 B2
8708965 Boyden et al. Apr 2014 B2
8712815 Nichols et al. Apr 2014 B1
8821446 Trautman Sep 2014 B2
8900181 Knowlton Dec 2014 B2
8900186 Pettis et al. Dec 2014 B2
8945060 Bunch Feb 2015 B2
9017289 Backes Apr 2015 B2
9017318 Fourkas Apr 2015 B2
9039688 Palmer, III May 2015 B2
9066712 Fourkas Jun 2015 B2
9072498 Elkins Jul 2015 B2
9101346 Burger Aug 2015 B2
9113855 Burger Aug 2015 B2
9149331 Deem Oct 2015 B2
9155584 Fourkas Oct 2015 B2
9180273 Konstantino Nov 2015 B2
9214030 Sole et al. Dec 2015 B2
9227023 Kraft Jan 2016 B2
9241753 Fourkas Jan 2016 B2
9254162 Burger Feb 2016 B2
9289605 Choi Mar 2016 B2
9314568 Gurtner et al. Apr 2016 B2
9468748 Bang Oct 2016 B2
20010008937 Callegaro et al. Jul 2001 A1
20020010433 Johnson Jan 2002 A1
20020026039 Bellini et al. Feb 2002 A1
20020065483 Leon May 2002 A1
20020133114 Itoh Sep 2002 A1
20020151843 Correa et al. Oct 2002 A1
20030028154 Ross Feb 2003 A1
20030050602 Pettis et al. Mar 2003 A1
20030078912 Oliver Apr 2003 A1
20030144632 Hommann et al. Jul 2003 A1
20030181863 Ackley Sep 2003 A1
20030199883 Laks Oct 2003 A1
20030233067 McIntosh et al. Dec 2003 A1
20040010224 Bodmeier Jan 2004 A1
20040015133 Karim Jan 2004 A1
20040092011 Wilkison et al. May 2004 A1
20040092927 Podhajsky et al. May 2004 A1
20040147883 Tsai Jul 2004 A1
20040192643 Pressato et al. Sep 2004 A1
20040220532 Caizza Nov 2004 A1
20050025755 Hedrick Feb 2005 A1
20050033362 Grafton Feb 2005 A1
20050085767 Menassa Apr 2005 A1
20050123895 Freund Jun 2005 A1
20050131353 Mossanen-Shams et al. Jun 2005 A1
20050137496 Walsh et al. Jul 2005 A1
20050147562 Hunter et al. Aug 2005 A1
20050177117 Crocker et al. Aug 2005 A1
20050182446 DeSantis Aug 2005 A1
20050215956 Nerney Sep 2005 A1
20050261633 Khalaj Nov 2005 A1
20060041320 Matsuda Feb 2006 A1
20060079765 Neer Apr 2006 A1
20060089594 Landau Apr 2006 A1
20060150742 Esnouf Jul 2006 A1
20070038181 Melamud Feb 2007 A1
20070083155 Muller Apr 2007 A1
20070085767 Jung et al. Apr 2007 A1
20070100363 Dollar et al. May 2007 A1
20070167920 Hommann Jul 2007 A1
20070191781 Richards et al. Aug 2007 A1
20070212385 David Sep 2007 A1
20070250010 Hohlfelder et al. Oct 2007 A1
20070251531 Khouri Nov 2007 A1
20070270710 Frass et al. Nov 2007 A1
20080015522 Yeshurun Jan 2008 A1
20080033347 D'Arrigo et al. Feb 2008 A1
20080058706 Zhang Mar 2008 A1
20080058839 Nobles Mar 2008 A1
20080071385 Binette et al. Mar 2008 A1
20080097325 Tanaka et al. Apr 2008 A1
20080108952 Horvath et al. May 2008 A1
20080114305 Gerondale May 2008 A1
20080119797 Kim May 2008 A1
20080119876 Price et al. May 2008 A1
20080161772 Nayak Jul 2008 A1
20080167674 Bodduluri et al. Jul 2008 A1
20080188816 Shimazaki Aug 2008 A1
20080200758 Orbay et al. Aug 2008 A1
20080243028 Howard et al. Oct 2008 A1
20080281278 Williams Nov 2008 A1
20080299213 Kleinsek Dec 2008 A2
20080317718 Yoshimura Dec 2008 A1
20090088703 Azar Apr 2009 A1
20090098177 Werkmeister et al. Apr 2009 A1
20090123547 Hill May 2009 A1
20090124552 Hill May 2009 A1
20090124996 Heneveld et al. May 2009 A1
20090125050 Dixon May 2009 A1
20090131886 Liu et al. May 2009 A1
20090143746 Mudd et al. Jun 2009 A1
20090162415 Huang et al. Jun 2009 A1
20090187118 Kim et al. Jul 2009 A1
20090234322 Fischer Sep 2009 A1
20090240200 Heneveld et al. Sep 2009 A1
20090246182 Casteilla Oct 2009 A1
20090247953 Yeshurun Oct 2009 A1
20090259180 Choi Oct 2009 A1
20090275917 Azar Nov 2009 A1
20090287161 Traub Nov 2009 A1
20090299328 Mudd et al. Dec 2009 A1
20090312746 Khouri Dec 2009 A1
20090317367 Chazenbalk Dec 2009 A1
20100006095 Woodcock Jan 2010 A1
20100010627 Matheny Jan 2010 A1
20100030152 Lee et al. Feb 2010 A1
20100069848 Alferness Mar 2010 A1
20100100114 Berger Apr 2010 A1
20100121307 Lockard May 2010 A1
20100152675 McClintock Jun 2010 A1
20100152679 Tezel Jun 2010 A1
20100179488 Spiegel Jul 2010 A1
20100256594 Kimmell et al. Oct 2010 A1
20100256596 Chomas Oct 2010 A1
20100279405 Peterson Nov 2010 A1
20100280488 Pruiitt et al. Nov 2010 A1
20100282774 Greter et al. Nov 2010 A1
20100286618 Choi Nov 2010 A1
20110009808 AlGhamdi Jan 2011 A1
20110021905 Patrick et al. Jan 2011 A1
20110028910 Weber Feb 2011 A1
20110070281 Altman et al. Mar 2011 A1
20110092916 Tezel et al. Apr 2011 A1
20110137286 Mudd et al. Jun 2011 A1
20110150823 Huang Jun 2011 A1
20110152926 Vetrecin Jun 2011 A1
20110160674 Holmes et al. Jun 2011 A1
20110172645 Moga Jul 2011 A1
20110190974 Holmes et al. Aug 2011 A1
20110202014 Mutzbauer Aug 2011 A1
20110213336 Cucin Sep 2011 A1
20110218494 Assaf Sep 2011 A1
20110218497 Assaf Sep 2011 A1
20110230839 Bahrami et al. Sep 2011 A1
20110238038 Sefi Sep 2011 A1
20110263724 Gurtner Oct 2011 A1
20110282324 Kurokawa et al. Nov 2011 A1
20110282381 Cronin et al. Nov 2011 A1
20110319865 Buss Dec 2011 A1
20120010146 Han et al. Jan 2012 A1
20120041374 Lee Feb 2012 A1
20120076868 Lamberti et al. Mar 2012 A1
20120089211 Curtis Apr 2012 A1
20120101475 Wilmot Apr 2012 A1
20120123194 Beckman May 2012 A1
20120123537 Manesis et al. May 2012 A1
20120141532 Blanda et al. Jun 2012 A1
20120150266 Shalev Jun 2012 A1
20120156265 Binette et al. Jun 2012 A1
20120209248 Gurtner et al. Aug 2012 A1
20120245629 Gross et al. Sep 2012 A1
20120259322 Fourkas Oct 2012 A1
20120265064 Bahrami et al. Oct 2012 A1
20120265171 Thorne Oct 2012 A1
20120296206 Bahrami et al. Nov 2012 A1
20130012865 Sallberg et al. Jan 2013 A1
20130041346 Alon Feb 2013 A1
20130096531 Estepa et al. Apr 2013 A1
20130122068 Fermanian et al. May 2013 A1
20130131632 Mudd et al. May 2013 A1
20130131633 Mudd et al. May 2013 A1
20130150826 Almohizea Jun 2013 A1
20130184648 Inou et al. Jul 2013 A1
20130184696 Fourkas Jul 2013 A1
20130197446 Gustafsson Aug 2013 A1
20130197449 Franklin et al. Aug 2013 A1
20130211374 Hetherington Aug 2013 A1
20130253289 Hadvary Sep 2013 A1
20130274655 Jennings Oct 2013 A1
20130274670 Mudd et al. Oct 2013 A1
20130280755 Hubert Oct 2013 A1
20130310763 Mudd et al. Nov 2013 A1
20140018770 Sutkin Jan 2014 A1
20140018835 Scherkowski Jan 2014 A1
20140066845 Mudd et al. Mar 2014 A1
20140088502 Matheny et al. Mar 2014 A1
20140088553 Hetherington Mar 2014 A1
20140114279 Klinghoffer Apr 2014 A1
20140121587 Sallberg et al. May 2014 A1
20140128685 Na May 2014 A1
20140128810 Ozawa et al. May 2014 A1
20140162901 Bahrami et al. Jun 2014 A1
20140170299 Gill Jun 2014 A1
20140228950 Whitcup et al. Aug 2014 A1
20140228971 Kim Aug 2014 A1
20140249504 Franklin et al. Sep 2014 A1
20140257179 Schwab et al. Sep 2014 A1
20140257190 Yue et al. Sep 2014 A1
20140309590 Bahrami et al. Oct 2014 A1
20140343481 Ignon Nov 2014 A1
20140350514 Levin Nov 2014 A1
20140350516 Schwab Nov 2014 A1
20140350517 Dominguez Nov 2014 A1
20140350518 Franklin et al. Nov 2014 A1
20140350536 Allison Nov 2014 A1
20150025459 Kimmel et al. Jan 2015 A1
20150025563 Mosharrafa et al. Jan 2015 A1
20150119875 Fischell et al. Apr 2015 A1
20150126929 Franklin et al. May 2015 A1
20150141956 Hoffman et al. May 2015 A1
20150157809 Park et al. Jun 2015 A1
20150209265 Horne Jul 2015 A1
20150343147 Franklin et al. Dec 2015 A1
20160007990 Solish et al. Jan 2016 A1
20160058488 Fourkas Mar 2016 A1
20160095984 Franklin et al. Apr 2016 A1
20160114144 Sumida Apr 2016 A1
20160144125 Franklin May 2016 A1
20160207253 Down et al. Jul 2016 A9
20160213854 Schwab et al. Jul 2016 A1
20160303314 Momose Oct 2016 A1
20170080154 Mudd et al. Mar 2017 A1
20170290987 Mandaroux et al. Oct 2017 A1
Foreign Referenced Citations (103)
Number Date Country
264261 Sep 1926 CA
2535071 Feb 2003 CN
200960353 Oct 2007 CN
0362484 Apr 1990 EP
0205915 Jul 1990 EP
0167662 Dec 1990 EP
0648474 Apr 1995 EP
0809968 Dec 1997 EP
1051988 Nov 2000 EP
1476202 Nov 2004 EP
1486218 Dec 2004 EP
1395320 Jun 2006 EP
1859827 Nov 2007 EP
1923086 May 2008 EP
2189173 May 2010 EP
2242525 Oct 2010 EP
2335755 Jun 2011 EP
2422832 Feb 2012 EP
2103262 Feb 2013 EP
2184016 Apr 2013 EP
2671516 Dec 2013 EP
53011 Sep 1945 FR
2622457 May 1989 FR
2857654 Jan 2005 FR
2336783 May 2003 GB
20120007473 Jan 2012 KR
101246570 Mar 2013 KR
20130036921 Apr 2013 KR
20130130436 Dec 2013 KR
20130132196 Dec 2013 KR
20140029007 Mar 2014 KR
2286803 Nov 2006 RU
WO 90001349 Feb 1990 WO
WO 92013579 Aug 1992 WO
WO 94012228 Jun 1994 WO
WO 96025965 Aug 1996 WO
1997028840 Aug 1997 WO
WO 99048601 Sep 1999 WO
WO 0100190 Jan 2001 WO
WO 02055135 Jul 2002 WO
WO 2004022603 Mar 2004 WO
WO 2005095225 Oct 2005 WO
WO 2006065837 Jun 2006 WO
WO 2008086479 Aug 2006 WO
2006118804 Nov 2006 WO
WO 2006133111 Dec 2006 WO
WO 2007092929 Aug 2007 WO
WO 2007095922 Aug 2007 WO
WO 2007124478 Nov 2007 WO
2007140381 Dec 2007 WO
WO 2008019265 Feb 2008 WO
WO 2008053481 May 2008 WO
WO 2008063569 May 2008 WO
WO 2008072229 Jun 2008 WO
WO 2008079824 Jul 2008 WO
WO 2008148026 Dec 2008 WO
WO 2008148071 Dec 2008 WO
WO 2009003135 Dec 2008 WO
2009035680 Mar 2009 WO
WO 2009047346 Apr 2009 WO
2009091099 Jul 2009 WO
WO 2009085548 Jul 2009 WO
WO 2009098666 Aug 2009 WO
WO 2009103818 Aug 2009 WO
WO 2009115581 Sep 2009 WO
WO 2009155583 Dec 2009 WO
WO 2009158145 Dec 2009 WO
WO 2010026299 Mar 2010 WO
WO 2010028025 Mar 2010 WO
WO 2010127310 Nov 2010 WO
2011016785 Feb 2011 WO
2011073796 Jun 2011 WO
2011075731 Jun 2011 WO
WO 2011072399 Jun 2011 WO
WO 2011109129 Sep 2011 WO
WO 2011109130 Sep 2011 WO
WO 2012006587 Jan 2012 WO
WO 2012019103 Feb 2012 WO
WO 2012054301 Apr 2012 WO
WO 2012054311 Apr 2012 WO
2012127856 Sep 2012 WO
2012172424 Dec 2012 WO
WO 2013005881 Jan 2013 WO
WO 2013054165 Apr 2013 WO
WO 2013055832 Apr 2013 WO
WO 2013082112 Jun 2013 WO
WO 2013106857 Aug 2013 WO
WO 2014026044 Feb 2014 WO
2014034032 Mar 2014 WO
2014064534 May 2014 WO
WO 2012174464 May 2014 WO
2014189161 Nov 2014 WO
2015007243 Jan 2015 WO
WO 2015020982 Feb 2015 WO
2013065235 Apr 2015 WO
2015064031 May 2015 WO
WO 2015105269 Jul 2015 WO
2015127339 Aug 2015 WO
WO 2015149031 Oct 2015 WO
2016008845 Jan 2016 WO
WO 2016022865 Feb 2016 WO
WO 2016033584 Mar 2016 WO
WO 2016033586 Mar 2016 WO
Non-Patent Literature Citations (21)
Entry
PCT/US2016/021838 International Search Report dated May 17, 2016.
Hamza, F., et al., A new external filling device in tissue expansion, Plastic and Reconstructive Surgery, Mar. 1998, 813-815, vol. 101, No. 3.
Indian Patent Application No. 190/CHE/2002, Filed Mar. 20, 2002, Published Feb. 3, 2006, Hindustan Latex Limited, Title: A Subcutaneous Tissue Expander.
Indian Patent Application No. 190/CHE/2002, Filing Date: Mar. 20, 2002, Publication Date: Feb. 3, 2006, Applicant: Hindustan Latex Limited (IN).
Indian Patent Specification, Patent No. 209387, Application No. 190/MAS/2002, Filing date: Mar. 20, 2002, Publication Date: Feb. 3, 2006, Date of Grant: Sep. 21, 2007, Applicant: Hindustan Latex Limited (IN).
Bleyer, “SIS Facial Implant 510(k) Summary,” Cook Biotech Inc. May 2005.
Davidenko et al., “Collagen-hyaluronic acid scaffolds for adipose tissue engineering”, ACTA Biomaterialia, vol. 6, No. 10, Oct. 1, 2010, pp. 3957-3968.
Galderma, “Restylane Smart Click System Injection Device,” Mar. 2015, retrieved from http://www.red-dot-21.com/products/restylane-smart-click-system-injection-device-22169.
Galderma, “New Restylane Skinboosters SmartClick delivery system wins prestigious Red Dot design award,” Jul. 4, 2014, retrieved from http://www.galderma.com/News/articleType/ArticleView/articleId/64/New-Restylane-Skinboosters-SmartClick-delivery-system-wins-prestigious-Red-Dot-design-award.
ISRWO from PCT/US2009/045831, dated Feb. 24, 2010.
ISRWO from PCT/US2014/039265.
ISRWO from PCT/US2014/039266.
Kilroy et al., “Cytokine Profile of Human Adipose-Derived Stem Cells: Expression of Angiogenic, Hematopoietic, and Pro-Inflammatory Factors,” J. Cell. Physiol., 2007, 702-709.
Park et al., “Biological characterization of EDC-crosslinked collagen-hyaluronic acid matrix in dermal tissue restoration”, Biomaterials, Elsevier Science Publishers BV, vol. 24, No. 9, Apr. 1, 2003, pp. 1631-1641.
PRIME Journal, “Galderma to launch two new syringes at AMWC 2014,” Mar. 2014.
Rehman et al., “Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal Cells,” Circulation, 2004, 1292-1298, 109.
Turtlepin, “The Painless Direct Dermal Injector” Product Information, JM Biotech Co Ltd, 2013.
Wang et al., “In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin.”, Archives of Dermatology, American Medical Association, US, vol. 143, No. 2, Feb. 1, 2007, pp. 155-163.
Yoshimura et al., “Cell-Assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/Stromal Cells,” Aesth. Plast. Surg., 2008, 48-55.
Yoshimura et al., “Cell-Assisted Lipotransfer for Facial Lipoatrophy: Effects of Clinical Use of Adipose-Derived Stem Cells,” Dermatol. Surg., 2008, 1178-1185.
Yoshimura et al., “Characterization of Freshly Isolated and Cultured Cells Derived From the Fatty and Fluid Portions of Liposuction Aspirates,” J Cell Physiol, 2006, 1011-1041.
Related Publications (1)
Number Date Country
20160263358 A1 Sep 2016 US
Provisional Applications (1)
Number Date Country
62131064 Mar 2015 US